

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number  
**WO 2005/000884 A1**

(51) International Patent Classification<sup>7</sup>:  
A61K 39/07, A61P 31/04, C07K 16/12

C07K 14/32,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2004/017736

(22) International Filing Date: 4 June 2004 (04.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/476,598

5 June 2003 (05.06.2003) US

(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report  
— with a declaration as to non-prejudicial disclosures or exceptions to lack of novelty

(48) Date of publication of this corrected version:

6 October 2005

(15) Information about Correction:

see PCT Gazette No. 40/2005 of 6 October 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and  
(75) Inventors/Applicants (for US only): SCHNEERSON, Rachel [US/US]; 10601 Weymouth Street, Bethesda, MD 20814 (US). LEPLA, Stephen [US/US]; 9501 Starmont Road, Bethesda, MD 20817 (US). ROBBINS, John, B. [US/US]; 3901 Rosemary Street, Chevy Chase, MD 20815 (US). SHILOACH, Joseph [US/US]; 1717 Mark Lane, Rockville, MD 20852 (US). KUBLER-KIELB, Joanna [PL/US]; 212 Congressional Lane #201, Rockville, MD 20852 (US). LIU, Darrell [US/US]; 8907 Burdette Road, Bethesda, MD 20817 (US). MAJADLY, Fathy [US/US]; 5640 Wade Court, Apt. G, Frederic, MD 21703 (US).

(74) Agent: SIEGEL, Susan, Alpert; Klarquist, Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(54) Title: POLY-GAMMA-GLUTAMIC CONJUGATES FOR ELICITING IMMUNE RESPONSES DIRECTED AGAINST BACILLI

(57) Abstract: Immunogenic compositions and methods for eliciting an immune response against *B. anthracis* and other bacilli are provided that include immunogenic conjugates of a poly- $\gamma$ -glutamic acid ( $\gamma$ PGA) polypeptides of *B. anthracis*, or of another *Bacillus* that expresses a  $\gamma$ PGA polypeptide. The  $\gamma$ PGA conjugates elicit an effective immune response against *B. anthracis*, or against another *Bacillus*, in mammalian hosts to which the conjugates are administered. The preferred conjugate consists of  $\gamma$ -D-PGA and *Bacillus* protective antigen.

WO 2005/000884 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number  
**WO 2005/000884 A1**

- (51) International Patent Classification<sup>7</sup>: **C07K 14/32**, A61K 39/07, A61P 31/04, C07K 16/12
- (74) Agent: **SIEGEL, Susan, Alpert**; Klarquist, Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).
- (21) International Application Number: **PCT/US2004/017736**
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: **4 June 2004 (04.06.2004)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data: **60/476,598** **5 June 2003 (05.06.2003)** **US**
- (71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SCHNEERSON, Rachel** [US/US]; 10601 Weymouth Street, Bethesda, MD 20814 (US). **LEPPLA, Stephen** [US/US]; 9501 Starmont Road, Bethesda, MD 20817 (US). **ROBBINS, John, B.** [US/US]; 3901 Rosemary Street, Chevy Chase, MD 20815 (US). **SHILOACH, Joseph** [US/US]; 1717 Mark Lane, Rockville, MD 20852 (US). **KUBLER-KIELB, Joanna** [PL/US]; 212 Congressional Lane #201, Rockville, MD 20852 (US). **LIU, Darrell** [US/US]; 8907 Burdette Road, Bethesda, MD 20817 (US). **MAJADLY, Fathy** [US/US]; 5640 Wade Court, Apt. G, Frederic, MD 21703 (US).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**  
— of inventorship (Rule 4.17(iv)) for US only
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments  
— with a declaration as to non-prejudicial disclosures or exceptions to lack of novelty
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **POLY-GAMMA-GLUTAMIC CONJUGATES FOR ELICITING IMMUNE RESPONSES DIRECTED AGAINST BACILLI**

(57) Abstract: Immunogenic compositions and methods for eliciting an immune response against *B. anthracis* and other bacilli are provided that include immunogenic conjugates of a poly- $\gamma$ -glutamic acid ( $\gamma$ PGA) polypeptides of *B. anthracis*, or of another *Bacillus* that expresses a  $\gamma$ PGA polypeptide. The  $\gamma$ PGA conjugates elicit an effective immune response against *B. anthracis*, or against another *Bacillus*, in mammalian hosts to which the conjugates are administered. The preferred conjugate consists of  $\gamma$ -D-PGA and *Bacillus* protective antigen.

WO 2005/000884 A1